Author of

• 17398

  +

  P2.01 - Poster Session with Presenters Present (ID 461)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17430

    +

    P2.01-032 - Impact of Preoperative Serum Anti-60S Ribosomal Protein L29 Levels on Prognosis in Patients Who Underwent Surgery for Non-Small Cell Lung Cancer (ID 4883)

    14:30 - 14:30  |  Author(s): T. Hayashi
    • Abstract
    • Slides

    Background:
    Ribosome is a subcellular organelle, which serves as the site of biological protein synthesis. Ribosomal protein L29 (RPL29) is one of the proteins composing ribosome, and it expresses in cell surface as well as in cytoplasm, especially showing its high expression in cancer cells.
    
    Methods:
    We retrospectively reviewed 92 patients who underwent surgical resection for non-small cell lung cancer between June 2010 and January 2012. Preoperative serum anti-RPL29 levels were measured by the indirect enzyme-linked immunosorbent assay. The cut-off value was represented by the median of anti-RPL29 levels.
    
    Results:
    The patients consisted of 60 males and 32 females, and their average age was 68.7 years (range: 44-87 years). Adenocarcinoma was the most common subtype (n = 69), which was followed by squamous cell carcinoma (n = 13), adenosquamous cell carcinoma (n = 4), pleomorphic carcinoma (n =4), and large cell carcinoma (n = 2). Postoperative pathological stage consisted of stage IA (n = 28), IB (n = 28), IIA (n = 11), IIB (n = 2), and IIIA (n = 23). EGFR activating mutations were found in 35 patients (32 adenocarcinomas, 2 adenosquamous cell carcinomas, and 1 pleomorphic carcinoma). The median of anti-RPL29 levels in 92 cases was 0.351. Three-year and five-year overall survival rate was 62.7% and 56.6%, respectively, in the patients whose serum anti-RPL29 level was less than the median, and 90.0% and 83.7%, respectively, in the patients with the median or more of anti-RPL29 levels (P = 0.005). In the multivariate Cox proportional hazard model, anti-RPL29 level being the median or more and pathological stage IA were identified as independent prognostic factors (P = 0.013 and P = 0.017, respectively).
    
    Conclusion:
    Serum anti-RPL29 levels may be a novel prognostic marker for non-small cell lung cancer.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.